Skip to main content

Advertisement

SpringerLink
Log in

Breast cancer expresses functional NMDA receptors

  • Preclinical study
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

We demonstrate here that functional NMDAR1 and NMDAR2 receptors are expressed by Mcf-7 and SKBR3 breast cancer cell lines, and possibly by most or all high-grade breast tumors, and that these receptors are important for the growth of human breast cancer xenografts in mice. RT-PCR demonstrated mRNA for both NMDAR1 and NMDAR2 receptors are expressed in both Mcf-7 and SKBR3 cell lines, and these messages likely have sequences identical to those reported for human mRNAs. Proteins of the expected respective sizes 120 and 170 kD are generated from these mRNAs by the tumor cells. Cell growth was found to be significantly (P < 0.0001) impaired down to 10% of normal growth by the irreversible NMDAR1 antagonists MK-801 and memantine with IC 50s ranging from 600 to >800 µM and from 200 to 300 µM for the two lines. Paradoxically, memantine with a lower binding affinity had the greater influence of the two inhibitors on cell viability. Immunohistochemical examination of high-grade invasive ductal and lobular breast cancer with our polyclonal antibodies against a peptide (-Met-Ser-Ile-Tyr-Ser-Asp-Lys-Ser-Ile-His-) in the extracellular domain of the NMDAR1 receptor gave specific positive staining for the receptor in all 10 cases examined. Positive staining was chiefly concentrated at the membranes of these tumor tissues. No staining with these antibodies was found for normal breast and kidney tissues. When Mcf-7 cells were grown as tumor xenografts in nu/nu mice, the growth of these tumors was completely arrested by daily treatments with MK-801 over 5 days. All of these data point to active NMDAR receptors being expressed by most breast cancers, and having an important influence on their survival.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. North WG, Fay MJ, Du JL, Cleary M, Gallagher JD, McCann FV (1997) Presence of functional NMDA receptors in a human neuroblastoma cell-line. Mol Chem Neuropathol 30:77–94

    Article  CAS  PubMed  Google Scholar 

  2. Danilczuk Z, Ossowska G, Lupina T, Ciesslik K, Zebrowska-Lupina I (2005) Effect of NMDA receptor antagonists on behavioral impairment induced by chronic treatment with dexamethasone. Pharmacol Rep 57:47–54

    CAS  PubMed  Google Scholar 

  3. Carpenter D (2002) NMDA receptors and the molecular mechanisms of excitotoxicity. In: Johnson P, Boldyrev AA (eds) Oxidative stress at the molecular, cellular, and organ levels. Research Signpost, Trivandrum, pp 77–88

    Google Scholar 

  4. Hinoi E, Takarada T, Ueshima T, Tsuchihashi Y, Yoneda Y (2004) Glutamate signaling in peripheral tissues. Eur J Biochem 271:1–13

    Article  CAS  PubMed  Google Scholar 

  5. Sonkusare SK, Kaul CL, Ramarao P (2005) Dementia of Alzheimer’s disease and other neurodegenerative disorders-memantine, a new hope. Pharmacol Rev 51:1–17

    CAS  Google Scholar 

  6. Plosker GL, Lyseng-Williamson KA (2005) Memantine: a pharmacoeconomic review of its use in moderate-to-severe Alzheimer’s disease. Pharmacoeconomics 23:193–206

    Article  PubMed  Google Scholar 

  7. Kashiwagi K, Masuko T, Nguyen CD, Kuno T, Tanaka I, Igarashi K, Williams K (2002) Channel blockers acting at N-methyl-D-aspartate receptors:differential effects of mutations in the vestibule and ion channel pore. Mol Pharmacol 61:533–545

    Article  CAS  PubMed  Google Scholar 

  8. Fredriksson A, Danysz W, Quack G, Archer T (2001) Co-administration of memantine and amantadine with sub/suprathreshold doses of L-dopa restores motor behaviour of MPTP-treated mice. J Neural Transm 108:167–187

    Article  CAS  PubMed  Google Scholar 

  9. North WG, Maurer LH, Valtin H, O’Donnell JF (1980) Human neurophysins as potential tumor markers for small-cell carcinoma of the lung: application of specific radioimmunoassays for vasopressin-associated and oxytocin-associated neurophysins. J Clin Endocrinol Metab 51:892–896

    Article  CAS  PubMed  Google Scholar 

  10. North WG, Pai S, Friedmann AS, Fay MJ, Yu X-M, Memoli VA (1995) Vasopressin gene-related products are markers of human breast cancer. Breast Cancer Res and Treat 34:229–235

    Article  CAS  Google Scholar 

  11. North WG (1991) Neuropeptide production by small cell carcinoma: vasopressin and oxytocin as plasma markers of disease. J Clin Endocrin Metab 73:1316–1320

    Article  CAS  Google Scholar 

  12. Moriyoshi K, Masu M, Ishu T, Shigemoto R, Mizuno N, Nakanishi S (1991) Molecular cloning and characterization of the rat NMDA receptor. Nature 354:31–37

    Article  CAS  PubMed  Google Scholar 

  13. Hess SD, Daggett LP, Crona J, Deal C, Lu C–C, Urrutia A, Chavez-Noriega L, Ellis SB, Johnson EC, Velicelebi G (1996) Cloning and functional characterisation of human heteromeric N-methyl-D-aspartate receptors. J Pharmacol Exper Therap 278:808–816

    CAS  Google Scholar 

  14. Ahmed SA, Gogal RM Jr, Walsh JE (1994) A new rapid and simple non-radioactive assay to monitor and determine the proliferation of lymphocytes: an alternative to [3H]thymidine incorporation assay. J Immunol Methods 170(2):211–224

    Article  CAS  PubMed  Google Scholar 

  15. Silverstein MJ et al (2002) International consensus Conference: Image-detected breast cancer: state of the art diagnosis and treatment. Breast J 8:70–76

    Article  Google Scholar 

  16. Pierce AGE (1969) The cytochemistry and ultrastructure of polypeptide hormone producing cells of the APUD series, and the embryologic, physiologic, and pathologic implications of the concept. J Histochem Cytochem 17:303–313

    Article  Google Scholar 

  17. North WG (2000) Gene regulation of vasopressin and vasopressin receptors in cancer. Exper Physiol 85S:27–40

    Article  Google Scholar 

  18. Roos DH, Puntel RL, Santos MM, Souza DO, Farina M, Nogueira CW, Aschner M, Burger ME, Barbosa NB, Rocha JB (2009) Guanosine and synthetic organoselenium compounds modulate methylmercury-induced oxidative stress in rat brain cortical slices: involvement of oxidative stress and glutamatergic system. Toxicol In Vitro 23:302–307

    Article  CAS  PubMed  Google Scholar 

  19. Longuemare MC, Keung EC, Chun S, Sharp FR, Chan PH, Swanson RA (1996) MK801 reduces uptake and stimulates efflux of excitatory amino acids via membrane depolarization. Am J Physiol 270:C1398–C1404

    CAS  PubMed  Google Scholar 

  20. Stepulak A, Sifringer M, Rzeski W, Endesfelder S, Gratopp A, Pohl EE, Bittigau P, Felderhoff-Mueser U, Kaindl AM, Bührer C, Hansen HH, Stryjecka-Zimmer M, Turski L, Ikonomidou C (2005) NMDA antagonist inhibits the extracellular signal-regulated kinase pathway and suppresses cancer growth. Proc Natl Acad Sci USA 102:15605–15610

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Tricklebank MD, Singh L, Oles RJ, Preston C, Iversen SD (1989) The behavioural effects of MK-801: a comparison with antagonists acting non-competitively and competitively at the NMDA receptor. Eur J Pharmacol 167:127–135

    Article  CAS  PubMed  Google Scholar 

  22. Kawabe K, Yoshihara T, Ichitani Y, Iwasaki T (1998) Intrahippocampal d-cycloserine improves MK-801-induced memory deficits: radial arm maze performance in rats. Brain Res 814:226–230

    Article  CAS  PubMed  Google Scholar 

  23. Gilbert ME (1988) The NMDA-receptor antagonist, MK-801, suppresses limbic kindling and kindled seizures. Brain Res 463:90–99

    Article  CAS  PubMed  Google Scholar 

  24. During MJ, Symes CW, Lawlor PA, Lin J, Dunning J, Fitzsimons HL, Poulsen D, Leone P, Xu R, Dicker BL, Lipski J, Young D (2000) An oral vaccine against NMDAR1 with efficacy in experimental stroke and epilepsy. Science:1453–1460

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgment

Launa Lynch was a postdoctoral fellow on NIH Training Grant T32 DK 07508 (William G. North, Director). Excellent technical assistance was provided by Alison North and Maudine Waterman.

Author information

Authors and Affiliations

  1. Dartmouth Medical School, Lebanon, NH, 03756, USA

    William G. North, Guohong Gao, Vincent A. Memoli & Launa Lynch

  2. Woomera Therapeutics Inc., Lebanon, NH, 03766, USA

    Roy H. Pang

Authors
  1. William G. North
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Guohong Gao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Vincent A. Memoli
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Roy H. Pang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Launa Lynch
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to William G. North.

Rights and permissions

Reprints and permissions

About this article

Cite this article

North, W.G., Gao, G., Memoli, V.A. et al. Breast cancer expresses functional NMDA receptors. Breast Cancer Res Treat 122, 307–314 (2010). https://doi.org/10.1007/s10549-009-0556-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-009-0556-1

Keywords

Search

Navigation